|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude显示文摘AIM:To use leptin-deficient(ob/ob) mice with demonstrated differences in steatosis levels to test a new diagnostic method using the acoustical structure quantification(ASQ) mode and the associated analytical parameter,'focal disturbance ratio'(FD-ratio).METHODS:Nine ob/ob mice,at 5,8,and 12 wk of age(n = 3 in each age group),were used as models for hepatic steatosis.Echo signals obtained from ultrasonography in the mice were analyzed by ASQ,which uses a statistical analysis of echo amplitude to estimate inhomogeneity in the diagnostic region.FD-ratio,as calculated from this analysis,was the focus of the present study.FD-ratio and fat droplet areas and sizes were compared between age groups.RESULTS:No fibrosis or inflammation was observed in any of the groups.The fat droplet area significantly(P < 0.01) increased with age from 1.25% ± 0.28% at 5 wk to 31.07% ± 0.48% at 8 wk to 51.69% ± 3.19% at 12 wk.The median fat droplet size also significantly(P < 0.01) increased with age,from 1.33(0.55-10.52) m at 5 wk,2.82(0.61-44.13) m at 8 wk and 6.34(0.66-81.83) m at 12 wk.The mean FD-ratio was 0.42 ± 0.11 at 5 wk,0.11 ± 0.05 at 8 wk,and 0.03 ± 0.02 at 12 wk.The FD-ratio was significantly lower at 12 wk than at 5 wk and 8 wk(P < 0.01).A significant negative correlation was observed between the FD-ratio and either the fat droplet area(r =-0.7211,P = 0.0017) or fat droplet size(r =-0.9811,P = 0.0052).CONCLUSION:This tool for statistical analysis of signals from ultrasonography using the FD-ratio can be used to accurately quantify fat in vivo in an animal model of hepatic steatosis,and may serve as a quantitative biomarker of hepatic steatosis. | Hidekatsu Kuroda Keisuke Kakisaka Naohisa Kamiyama Takayoshi Oikawa Mio Onodera Kei Sawara Kanta Oikawa Ryujin Endo Yasuhiro Takikawa Kazuyuki Suzuki | 2012 | World Journal of Gastroenterology2012，18，29： | 15 |
| 2 | Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma显示文摘AIM:To evaluate the efficacy of transcatheter arterial chemoembolization(TACE) using a suspension of a fine-powder formulation of cisplatin(DDPH) for hepatocellular carcinoma(HCC).METHODS:The study population was comprised of 164 patients who were treated by TACE alone.Of these patients,76 underwent TACE using a suspension of DDPH in lipiodol(LPD)(DDPH group),and the remaining 88 underwent TACE with an emulsion of doxorubicin(ADM) with LPD(ADM group).We compared the DDPH group with the ADM group in terms of the objective early response rate,progression free survival(PFS) and overall survival(OS).RESULTS:The objective early response rate in the DDPH group was significantly higher than that in the ADM group(54% vs 24%,P < 0.001).The PFS rate in the DDPH group was also significantly higher than that in the ADM group(P < 0.001).Moreover,the OS in the DDPH group was significantly longer than that in the ADM group(P = 0.002).Although the incidence rate of nausea or vomiting in the DDPH group was higher than that in the ADM group,the ADM group showed a higher incidence rate of the adverse events of hepatic arterial damage and leucopenia.No other serious complications were observed in either group.CONCLUSION:We conclude that TACE using a suspension of DDPH in LPD could be a useful treatment for HCC. | Kazuhiro Kasai Akira Ushio Kei Sawara Yasuhiro Miyamoto Yukiho Kasai Kanta Oikawa Hidekatsu Kuroda Yasuhiro Takikawa Kazuyuki Suzuki | 2010 | World Journal of Gastroenterology2010，16，27： | 6 |
| 3 | Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: A case report显示文摘The anti-arrhythmic agent amiodarone (AD) is associated with numerous adverse effects, but serious liver disease is rare. The improved safety of administration of daily low doses of AD has already been established and this regimen is used for long-term medication. Nevertheless,asymptomatic continuous liver injury by AD may increase the risk of step-wise progression of non-alcoholic fatty liver disease. We present an autopsy case of AD-induced liver cirrhosis in a patient who had been treated with a low dose of AD (200 mg/d) daily for 84 mo. The patient was a 85-year-old male with a history of ischemic heart disease.Seven years after initiation of treatment with AD, he was admitted with cardiac congestion. The total dose of AD was 528 g. Mild elevation of serum aminotransferase and hepatomegaly were present. Liver biopsy specimens revealed cirrhosis, and under electron microscopy numerous lysosomes with electron-dense, whorled, lamellar inclusions characteristic of a secondary phospholipidosis were observed. Initially, withdrawal of AD led to a slight improvement of serum aminotransferase levels, but unfortunately his general condition deteriorated and he died from complications of pneumonia and renal failure.Long-term administration of daily low doses of AD carries the risk of progression to irreversible liver injury. Therefore,periodic examination of liver function and/or liver biopsy is required for the management of patients receiving long-term treatment with AD. | Hiroki Oikawa Chihaya Maesawa Ryo Sato Kanta Oikawa Hiroyuki Yamada Seizo Oriso Sadahide Ono Akiko Yashima-Abo Koji Kotani Kazuyuki Suzuki Tomoyuki Masuda | 2005 | World Journal of Gastroenterology2005，11，34： | 4 |
| 4 | Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma显示文摘AIM:To evaluate the efficacy of transarterial chemoembolization(TACE) using a suspension of a finepowder formulation of cisplatin(DDPH) in lipiodol(LPD) in the treatment of hepatocellular carcinoma(HCC).METHODS:The subjects were 262 HCC patients treated with TACE using a DDPH-LPD suspension.The DDPH-LPD suspension was prepared by mixing 50 mg of DDPH into 10 mL of LPD.TACE was repeated when treated lesions relapsed and/or new hepatic lesions were detected.These patients received additional TACE using the same agent.TACE was repeated until complete regression of the tumor was obtained.The primary efficacy endpoint of the current study was the objective early response rate.Secondary efficacy endpoints were progression-free survival(PFS) and overall survival.RESULTS:The objective early response rate was 43.6%.Cumulative PFS rates were 56.7% at 6 mo,23.1% at 12 mo,13.4% at 18 mo,and 10.5% at 24 mo.The median PFS was 6.6 mo.Cumulative survival rates were 90.6% at 6 mo,81.9% at 12 mo,70.5% at 24 mo,and 58.8% at 36 mo.Median survival time was 46.6 mo.All adverse reactions were controllable by temporary suspension of treatment.No serious complications or treatment-related deaths were observed.CONCLUSION:TACE using a suspension of DDPH in LPD may be a useful treatment for HCC. | Kazuhiro Kasai Akira Ushio Yukiho Kasai Kei Sawara Yasuhiro Miyamoto Kanta Oikawa Yasuhiro Takikawa Kazuyuki Suzuki | 2013 | World Journal of Gastroenterology2013，19，14： | 3 |
| 5 | A disintegrin and metalloproteinase 17 (ADAM17) mediates epidermal growth factor receptor transactivation by angiotensin II on hepatic stellate cells显示文摘 | Hiroki Oikawa Chihaya Maesawa Yoshinori Tatemichi Yutaka Nishinari Masao Nishiya Hisata Mizugai Aya Ikeda Kanta Oikawa Yasuhiro Takikawa Tomoyuki Masuda | 2014 | Life Sciences2014，，： | 1 |
| 6 | Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma显示文摘 | Hidekatsu Kuroda Kazuhiro Kasai Keisuke Kakisaka Yuki Yasumi Koujiro Kataoka Akira Ushio Yasuhiro Miyamoto Kei Sawara Kanta Oikawa Koryo Kondo Yoshiaki Miura Ryujin Endo Yasuhiro Takikawa Kazuyuki Suzuki | 2010 | Hepatology Research2010，，5： | 1 |
| 7 | Therapeutic efficacy of combination therapy with intra‐arterial 5‐fluorouracil and systemic pegylated interferon α‐2b for advanced hepatocellular carcinoma with portal venous invasion显示文摘 | Kazuhiro Kasai Akira Ushio Yukiho Kasai Kei Sawara Yasuhiro Miyamoto Kanta Oikawa Hidekatsu Kuroda Yasuhiro Takikawa Kazuyuki Suzuki | 2011 | Cancer2011，，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员